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Ingestion of arsenic through contaminated 
drinking water is a major health concern in 
Bangladesh, where approximately 35 million 
people are chronically exposed (Kinniburgh 
and Smedley 2001). This exposure has been 
linked to increased risks of cancers of the 
skin, bladder, liver, and lung [California 
Environmental Protection Agency (EPA) 
2004; Navarro et al. 2007], as well as ischemic 
heart disease and neurologic impairments 
(Navarro et al. 2007). 
Metabolism of As occurs through a 
series of reduction and methylation reactions 
(Figure 1). The methylation steps are cata-
lyzed by arsenic methyltransferase (AS3MT), 
with S-adenosylmethionine (SAM) serving as 
the methyl donor (Lin et al. 2002; Marafante 
and Vahter 1984). Inorganic arsenite is first 
methylated to monomethylarsonic acid 
(MMAV). Upon reduction to MMAIII, it then 
undergoes a second methylation to dimethyl-
arsinic acid (DMAV). Methylation has gener-
ally been considered a detoxification pathway 
that generates the least toxic organic mamma-
lian arsenical metabolite, DMAV, and facili-
tates urinary excretion (Vahter and Marafante 
1987). However, increasing evidence suggests 
that MMAIII is a highly cytotoxic and geno-
toxic intermediate (Styblo et al. 2002; Wang 
et al. 2007). 
Folate, cobalamin (vitamin B12), and 
vitamin B6 are required for the recruitment 
and transfer of methyl groups in one-carbon 
metabolism. Other nutrients, including pro-
tein, betaine, and choline, also contribute to 
the availability of methyl groups ultimately 
used in SAM biosynthesis. Arsenic retention in 
tissues is increased with dietary methyl donor 
deficiency (Vahter and Marafante 1987), and 
urinary As (uAs) excretion is decreased in 
folate deficiency (Spiegelstein et al. 2003). 
Our previous work has shown that individual 
variation in the ability to methylate As is asso-
ciated with folate status (Gamble et al. 2005b; 
2006; 2007). However, few investigations of 
the association between cobalamin and As 
metabolism have been conducted, despite its 
critical role as an essential cofactor for methi-
onine synthase, which catalyzes the rem-
ethylation of homocysteine to methionine, a 
critical step in SAM biosynthesis. Zakharyan 
and Aposhian (1999) reported that in vitro 
incubation of methylcobalamin (CH3B12) 
with arsenite in the presence of a reducing 
agent can produce MMA and trace amounts 
of DMA nonenzymatically. We observed no 
association between plasma cobalamin and 
uAs metabolites in our previous cross-sectional 
study of 300 adults (Gamble et al. 2005b). 
Because the primary aim of that study was to 
examine the influence of folate on As methyla-
tion, we excluded cobalamin-deficient partici-
pants, thereby restricting the range of plasma 
cobalamin values. 
To examine the influence of a full range 
of plasma cobalamin concentrations on As 
metabolism, we conducted a cross-sectional 
study in which we oversampled cobalamin-
deficient participants (plasma cobalamin 
< 185 pmol/L). We also set out to replicate 
the in vitro work of Zakharyan and Aposhian 
(1999) in a slightly modified system, as this 
finding would contribute to our understand-
ing of the role that cobalamin might play in 
influencing the metabolism of As. 
Materials and Methods 
Study participants, procedure, and ethics. 
Using biologic samples from our original 
cross-sectional study of a random sample 
of 1,650 adults [the Nutritional Influences 
on Arsenic Toxicity study (Gamble et al. 
2005a)], we analyzed uAs metabolites for all 
of the cobalamin-deficient participants (n = 
412 with plasma cobalamin < 185 pmol/L). 
For efficiency, we combined these individu-
als with an additional 366 nondeficient 
partici  pants who already had uAs metabolite 
data, to incorporate a broad range of coba-
lamin nutritional status. This process yielded 
a total of 778 participants. All participants 
had provided blood and urine samples, and 
demographic information was obtained from 
a baseline survey. All study subjects gave 
informed oral consent to Bangladeshi field 
staff physicians before participating in the 
study. The research protocol was approved by 
the Institutional Review Board of Columbia 
University and the Bangladesh Medical 
Research Council. 
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Ba c k g r o u n d: Arsenic is a carcinogen to which 35 million people in Bangladesh are   chronically 
exposed. The enzymatic transfer of methyl groups to inorganic As (iAs) generates monomethyl-
arsonic (MMA) and dimethylarsinic acids (DMA) and facilitates urinary As (uAs) elimination. This 
process is dependent on one-carbon metabolism, a pathway in which folate and cobalamin have 
essential roles in the recruitment and transfer of methyl groups. Although DMAV is the least toxic 
metabolite, increasing evidence suggests that MMAIII may be the most cytotoxic and genotoxic As 
intermediary metabolite. 
oB j e c t i v e: We examined the associations between plasma cobalamin and uAs metabolites.
Me t h o d s : We conducted a cross-sectional study of 778 Bangladeshi adults in which we over-
sampled cobalamin-deficient participants. Participants provided blood samples for the measurement 
of plasma cobalamin and urine specimens for As measurements. 
re s u l t s: Cobalamin was inversely associated with the proportion of total uAs excreted as iAs 
(%iAs) [unstandardized regression coefficient (b) = –0.10; 95% confidence interval (CI), –0.17 to 
–0.02; p = 0.01] and positively associated with %MMA (b = 0.12; 95% CI, 0.05 to 0.20; p = 0.001). 
Both of these associations were stronger among folate-sufficient participants (%iAs: b = –0.17; 95% 
CI, –0.30 to –0.03; p = 0.02. %MMA: b = 0.20; 95% CI, 0.11 to 0.30; p < 0.0001), and the differ-
ences by folate status were statistically significant. 
co n c l u s i o n s: In this group of Bangladeshi adults, cobalamin appeared to facilitate the first As 
methylation step among folate-sufficient individuals. Given the toxicity of MMAIII, our findings 
suggest that in contrast to folate, cobalamin may not favorably influence As metabolism. 
key w o r d s : arsenic, Bangladesh, cobalamin, creatinine, dimethylarsinic acid, folate, homocysteine, 
monomethylarsonic acid, one-carbon metabolism. Environ Health Perspect 117:1724–1729 (2009). 
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Collection of biospecimens. Blood samples 
were collected by venipuncture from partici-
pants who had been sitting for 10–15 min. 
The samples were collected into EDTA-
containing tubes that were immediately 
placed in IsoRack cool packs (Brinkmann 
Instruments, Westbury, NY, USA). Samples 
were transported by hand (in coolers contain-
ing additional ice packs) to our field clinic in 
Araihazar within 4 hr of collection. The sam-
ples were then centrifuged at 4°C to separate 
plasma and cells. Plasma was stored at –80°C 
and shipped frozen on dry ice to Columbia 
University for analysis. Urine samples were 
collected in 50-mL acid-washed tubes, frozen 
at –20°C, and shipped on dry ice. 
  Measurement of plasma nutrients. 
Plasma cobalamin and folate were analyzed 
by radioimmunoassay (Quantaphase II; Bio-
Rad Laboratories, Richmond, CA, USA) as 
previously described (Gamble et al. 2005a; 
Pfeiffer et al. 2005). The within-day coeffi-
cient of variation (CV) was 3% for folate and 
4% for cobalamin. The between-day CV was 
11% for folate and 8% for cobalamin. We 
measured plasma total homocysteine (tHcys) 
using high-performance liquid chromatog-
raphy (HPLC) with fluorescence detection 
(Pfeiffer et al. 1999) as described previously 
(Gamble et al. 2005a). 
Well water As. We used graphite furnace 
atomic absorption (GFAA), with a detec-
tion limit of 5 µg/L, to measure total As in 
well-water samples. Samples found to have 
a concentration < 5 µg/L were reanalyzed by 
inductively coupled plasma-mass spectrom-
etry (ICP-MS), for which the detection limit 
was 0.1 µg/L (Cheng et al. 2004).
Total uAs and creatinine. Total uAs was 
measured in the Columbia University Trace 
Metals Core Laboratory by GFAA spectrom-
etry using the Analyst 600 graphite furnace 
system (PerkinElmer, Shelton, CT, USA), 
according to the method of Nixon et al. 
(1991). Our laboratory participates in a quality 
control program organized by Philippe Weber 
at the Quebec Toxicology Center in Quebec, 
Canada. Intraclass correlation coefficients 
between our laboratory’s values and samples 
calibrated at the Quebec laboratory were 0.99. 
We used a method based on the Jaffe reac-
tion (Slot 1965) to measure urinary creatinine   
concentrations. 
uAs metabolites. As metabolites were 
speciated using HPLC separation of arseno-
betaine (AsB), arsenocholine (AsC), arsen-
ate, arsenite, MMA, and DMA, followed 
by detection using ICP-MS. We calculated 
the percentages of iAs (iAsIII+V), MMA 
(MMAIII+V), and DMA (DMAIII+V) after 
subtracting AsC and AsB from the total.
Assay for in vitro generation of MMA and 
DMA by methylcobalamin and iAsIII. Because 
our epidemiologic data suggested a role for 
cobalamin in the generation of MMA, but 
not DMA, we sought to replicate the find-
ings of Zakharyan and Aposhian (1999) 
that suggested methylcobalamin could non-
enzymatically transfer its methyl group to 
arsenite. We modified their system so as to not 
include SAM. ArseniteIII, cobalamin, CH3B12, 
l-glutathione (GSH), MMA, and DMA were 
purchased from Sigma (St. Louis, MO, USA). 
Arsenate was purchased from PerkinElmer. All 
other chemicals were analytical reagent grade. 
Water was distilled and deionized. The assay 
for nonenzymatic arsenite methylation was 
done using 0.05 M Tris-HCl buffer at various 
pH values containing 10 mM GSH. At each 
pH, we used molar ratios of CH3B12:arsenite 
of 1:5, 3:5, and 5:5. We performed three rep-
licates for every combination of pH and molar 
ratio. The reaction mixture was incubated for 
1.5, 3, 6, 9, 12, and 30 hr at 37°C. At each 
time point we aliquoted 50 µL of the mixture, 
diluted it with mobile phase (10 mM ammo-
nium phosphate plus 10 mM ammonium 
nitrate), injected it onto the HPLC column, 
and detected concentrations of MMA, DMA, 
AsIII, and AsV by ICP-MS with dynamic 
reaction cell technology (ICP-MS-DRC). 
Calibration standards of a mixture of As 
metabolites were similarly processed. ICP-
MS-DRC coupled to HPLC separates and 
detects 7 As metabolites chromatographically 
separated by anion exchange with the use of 
a PRP-X100 column (Hamilton Co, Reno, 
NV, USA). 
Statistical analysis. Plasma nutrients and 
uAs metabolites were not normally distributed. 
We therefore used nonparametric tests where 
appropriate and natural log transformations 
that may either create approximately normal 
distributions for dependent variables in lin-
ear regression analysis, improve linearity in 
the relationship between an independent and 
dependent variable, or reduce the impact of 
extreme values of an independent variable in 
fitting linear models. We calculated descriptive 
statistics separately by sex for general charac-
teristics as well as for plasma nutrient and uAs 
metabolite concentrations. We tested for sex 
Figure 1. Arsenate is reduced to arsenite in a reaction thought to be dependent on GSH or other 
  endogenous reductants. Arsenite then undergoes an oxidative methylation, with SAM as the methyl 
donor, forming MMAV and SAH. MMAV is reduced to MMAIII and then undergoes a subsequent oxidative 
  methylation step to produce DMAV and SAH. 
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differences using the Wilcoxon rank-sum test 
for continuous variables and the chi-square 
test for categorical variables. The correlations 
between plasma cobalamin and covariates 
and between cobalamin and the percentage of 
As metabolites in urine were examined using 
Spearman’s correlation coefficients. We used 
linear regression models to examine associa-
tions between plasma cobalamin and the out-
come variables %iAs, %MMA, and %DMA 
in urine. Potential confounders considered for 
inclusion in the regression models were age, 
sex, urinary creatinine, body mass index (BMI), 
and total uAs. We used a Wald test to detect 
differences in the covariate-adjusted associa-
tions between cobalamin and uAs metabolites 
by sex, folate status, or water As status. We 
ran separate linear regression models to exam-
ine the covariate-adjusted associations between 
plasma cobalamin and each of the uAs metabo-
lites and to examine the differences in these 
associations by sex, folate status, or water As 
status. Analyses were performed using SAS 9.1 
(SAS Institute Inc., Cary, NC, USA). All sta-
tistical tests were two-sided with a significance 
level of 0.05. The As metabolite concentrations 
detected in the nonenzymatic laboratory assay 
experiments were expressed as a percentage of 
total detected metabolites. 
Results
Cross-sectional study of cobalamin and uAs 
metabolites. The general characteristics and 
plasma nutrient concentrations of the study 
participants by sex are shown in Table 1. The 
men in this sample were significantly older 
than the women and had a lower mean BMI. 
Nearly 60% of men were current cigarette 
smokers compared with 3% of women. Both 
women (30.6%) and men (40.9%) had a high 
prevalence of current betel nut use. Water As 
concentrations of the wells that served as the 
primary source of drinking water were above 
the Bangladeshi standard (50 µg/L) for 60% 
of women and 58% of men. The water As 
concentrations were above the World Health 
Organization standard (10 µg/L) for 81% of 
women and 83% of men.
Because we oversampled cobalamin- 
deficient participants, a large proportion of the 
sample had cobalamin deficiency: 57.6% of 
women and 46.8% of men had < 185 pmol/L. 
We used cutoff values of < 9.0 nmol/L for 
folate deficiency (Christenson et al. 1985), 
and ≥ 10.4 for women and ≥ 11.4 µmol/L 
for men for hyperhomocysteinemia [National 
Health and Nutrition Examination Survey 
III (Selhub et al. 1999)]; folate deficiency and 
hyper  homo  cysteinemia were very common, 
particularly in men (Table 1). We observed an 
inverse correlation between plasma cobalamin 
and tHcys concentrations (females: r = –0.26, 
p < 0.0001; males: r = –0.47, p < 0.0001). 
Mean water As concentrations did not dif-
fer significantly by sex (Table 2). As expected, 
mean urinary creatinine concentrations were 
higher among males than among females, 
although this difference did not achieve sta-
tistical significance in this sample (Table 2). 
Mean concentrations of uAs were similar for 
males and females; however, uAs per gram crea-
tinine (uAs/gCr) was significantly higher among 
females than among males. Women had sig-
nificantly lower percentages of As in urine pres-
ent as MMA (%MMA) and higher as DMA 
Table 1. General characteristics of the study sample.
Female (n = 479) Male (n = 299)
Characteristic Mean ± SD Median (range) Mean ± SD Median (range) p-Valuea
Age (years) 33.7 ± 8.8 32.0 (18.0–58.0) 42.9 ± 10.2 42.0 (21.0–67.0) < 0.0001
Height (cm) 149.7 ± 5.2 149.6 (133.0–165.0) 161.8 ± 5.5 161.9 (145.4–176.7) < 0.0001
Weight (kg) 45.3 ± 7.7 44.8 (27.8–73.7) 50.7 ± 8.3 50.0 (32.0–81.8) < 0.0001
BMI (kg/m2) 20.2 ± 3.1 19.8 (14.3–33.3) 19.4 ± 2.8 18.8 (13.7–31.5) 0.0001
BMI < 18.5 (%) 31.6 45.6 < 0.0001
Current smoking (%) 2.9 59.1 < 0.0001
Current betel nut use (%) 30.6 40.9 0.003
Education (years) 3.1 ± 3.5 2.0 (0–14) 3.8 ± 3.9 3.0 (0–16.0) 0.02
Type of housing (%)
Thatched 7.7 7.4 0.49
Corrugated tin 77.7 80.9
Other 14.6 11.7
Water As > 50 µg/L (%) 60.5 57.9 0.46
Water As > 10 µg/L (%) 81.4 83.3 0.51
Plasma cobalamin (pmol/L) 217.3 ± 114.6 175.9 (73.8–1171.8) 241.7 ± 117.2 197.7 (73.8–678.7) 0.0006
Plasma cobalamin < 151 pmol/L (%)b 26.5 19.4 0.02
Plasma cobalamin < 185 pmol/L (%)c 57.6 46.8 0.003
Plasma folate (nmol/L) 13.2 ± 9.3 10.1 (2.9–66.2) 9.4 ± 7.1 7.2 (2.6–52.7) < 0.0001
Plasma folate < 9.0 nmol/L (%)b 42.0 69.2 < 0.0001
Plasma tHcys (µmol/L) 9.7 ± 5.0 8.8 (0.2–46.8) 16.5 ± 11.8 13.4 (3.0–90.1) < 0.0001
Hyperhomocysteinemia (%)d 29.7 65.1 < 0.0001
aFor test of difference by sex, based on Wilcoxon’s rank-sum test for continuous variables and chi-square or Fisher’s exact test for categorical variables. bBased on reference values 
from Christenson et al. (1985). cBased on reference values from Pfeiffer et al. (2005). dDefined as ≥ 10.4 µmol/L for women and as ≥ 11.4 µmol/L for men.
Table 2. Mean concentrations of As variables and urinary creatinine, by sex and cobalamin status.
Female (n = 479) Male (n = 299) Cobalamin sufficient (n = 362) Cobalamin deficient (n = 416)
Variable [mean (95% CI)] [mean (95% CI)] p-Valuea [mean (95% CI)] [mean (95% CI)] p-Valueb
Water As (µg/L) 104.8 (95.3–114.3) 101.3 (89.6–113.0)  0.59 95.7 (85.0–106.4) 110.2 (100.0–120.3) 0.006
Urinary creatinine (mg/dL) 58.9 (55.2–62.7) 66.4 (60.8–72.1) 0.12 62.9 (58.1–67.6) 60.9 (56.6–65.1) 0.49
uAs (µg/L) 141.1 (130.3–151.9) 141.7 (125.0–158.5) 0.18 136.8 (123.5–150.1) 145.3 (132.4–158.1) 0.16
uAs/gCr 293.3 (271.0–315.6) 242.9 (221.2–264.6) 0.002 263.5 (237.8–289.2) 283.0 (262.7–303.2) 0.004
%iAs 15.7 (15.0–16.4) 15.0 (14.4–15.6) 0.54 15.7 (14.9–16.5) 15.2 (14.6–15.8) 0.92
%MMA 10.7 (10.3–11.1) 14.5 (13.9–15.1) < 0.0001 13.2 (12.7–13.7) 11.2 (10.8–11.7) < 0.0001
%DMA 73.6 (72.8–74.4) 70.5 (69.5–71.4) < 0.0001 71.1 (70.1–72.0) 73.6 (72.8–74.3) < 0.0001
MMA:iAs Ratio 0.79 (0.75–0.83) 1.07 (1.0–1.1) < 0.0001 0.99 (0.93–1.04) 0.82 (0.78–0.86) < 0.0001
DMA:MMA Ratio 8.5 (8.1–9.0) 5.7 (5.3–6.0) < 0.0001 6.5 (6.1–6.9) 8.2 (7.8–8.7) < 0.0001
aWilcoxon’s rank sum test for sex difference. bWilcoxon’s rank sum test for difference by cobalamin status.Cobalamin and arsenic metabolism
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(%DMA), suggesting a higher As methylation 
capacity in women for the second methyla-
tion step (Table 2). Mean concentrations of As 
variables by cobalamin status are also shown 
in Table 2. Both water As and uAs/gCr were 
higher among   cobalamin-deficient participants. 
Urinary %MMA was higher and %DMA was 
lower among cobalamin-sufficient participants 
than among cobalamin-deficient participants. 
In bivariate analysis, plasma cobalamin was 
inversely correlated with both water As and 
uAs/gCr (Table 3). We noted a statistically 
significant positive correlation between cobala-
min and %MMA (r = 0.18, p < 0.0001). Both 
%iAs and %DMA were weakly inversely corre-
lated with cobalamin concentration, and these 
associations appeared to be the same in males 
and females (Table 3). In linear regression 
models (Table 4), cobalamin was significantly 
inversely associated with %iAs [unstandard-
ized regression coefficient (b) = –0.10; 95% 
confidence interval (CI), –0.17 to –0.02; p = 
0.01] and positively associated with %MMA 
(b = 0.12; 95% CI, 0.05 to 0.20; p = 0.001) 
after adjusting for age, sex, urinary creatinine, 
total uAs, and BMI. These associations were 
stronger among females than among males, but 
the difference was not statistically significantly 
(Table 4). Cobalamin was not significantly 
associated with urinary %DMA. Because 
the influence of cobalamin on As methyla-
tion could depend on an adequate supply of 
5-methyl tetra  hydro  folate (THF), we further 
examined associations between cobalamin and 
uAs metabolites by folate status (Table 4). 
Plasma cobalamin was significantly inversely 
associated with %iAs (b = –0.17; 95% CI, 
–0.30 to –0.03; p = 0.02) and positively 
associated with %MMA (b = 0.20; 95% CI, 
0.11 to 0.30; p < 0.0001) only among folate-
sufficient subjects (p-value for test of difference 
by folate status was 0.06 for %iAs and 0.04 
for %MMA). We also examined associations 
between plasma cobalamin and uAs metabo  lites 
by water As concentrations ≤ 50 and > 50 µg/L 
(Table 4). The inverse association with %iAs 
was apparent only among those with water 
As concentrations ≤ 50 µg/L (b = –0.25; 95% 
CI, –0.40 to –0.09; p = 0.002); this difference 
was statistically significant (p = 0.005). Plasma 
cobalamin was significantly positively associ-
ated with %MMA in both strata of water As 
concentrations. Cobalamin was not signifi-
cantly associated with urinary %DMA in either 
strata of water As.
In vitro nonenzymatic As methylation by 
methylcobalamin. Incubation of arsenite with 
methylcobalamin in the presence of GSH 
resulted in the production of MMA (Figure 2). 
The amount of MMA increased with increasing 
molar ratios of CH3B12:arsenite and was high-
est with a molar ratio of 5:5 at a pH of 7.4. The 
amount of MMA also increased as the incuba-
tion period increased but appeared to plateau 
at approximately 9 hr. Very small amounts of 
DMA (i.e., < 0.05%) were also detected after 
6–9 hr of incubation (data not shown). 
Discussion
This study complements our previous work 
in Bangladesh, in which we have investigated 
the contributions of folate and tHcys to varia-
tions in As methylation. In our study region 
in Araihazar, Bangladesh, the prevalence of 
cobalamin deficiency (8% of men and 13% 
of women < 151 pmol/L) is much lower than 
that of folate deficiency (57% of men and 39% 
of women < 9 nmol/L) (Gamble et al. 2005a). 
The current cross-sectional study, in which we 
oversampled cobalamin-deficient individuals, 
allowed us to examine a full range of plasma 
cobalamin values in relation to As metabolism. 
Our results showed that plasma cobalamin was 
inversely associated with %iAs and positively 
associated with %MMA in urine. Both of 
these associations were stronger among folate-
sufficient individuals. 
In addition to our previous cross-sectional 
study (Gamble et al. 2005b), six other studies 
(Chung et al. 2006; Hall et al. 2007; Heck 
et al. 2007; Li et al. 2008; Pilsner et al. 2009; 
Zablotska et al. 2008) have examined the role 
of cobalamin in relation to As metabolism or 
susceptibility to the health effects of As expo-
sure. In our previous cross-sectional study of 
1,016 Bangladeshi adults (Heck et al. 2007), 
we reported that dietary cobalamin intake as 
calculated from a food frequency question-
naire was inversely associated with %iAs and 
positively associated with %MMA in urine. 
These associations persisted after adjusting for 
age, sex, total caloric intake, cigarette smok-
ing, and total uAs and are consistent with 
our current observations. In our recent cross-
sectional study among 10,628 Bangladeshi 
adults chronically exposed to As, dietary 
cobalamin intake was not significantly asso-
ciated with the odds of having skin lesions 
Table 3. Spearman’s correlation coefficients between cobalamin and As variables by sex.
Total sample
Sex
Variable M (n = 299) F (n = 479)
Water As (µg/L) –0.08* –0.04  –0.11*
Urinary creatinine (mg/dL) 0.07  0.09  0.04 
uAs (µg/L) –0.03  0.04  –0.08 
uAs/gCr –0.12# –0.04  –0.15**
Urinary %iAs –0.06  –0.02  –0.09 
Urinary %MMA 0.18## 0.10  0.18#
Urinary %DMA –0.08* –0.05  –0.05 
*p < 0.05. **p < 0.01. #p < 0.001. ##p < 0.0001.
Table 4. Parameter estimates for effect of increasing log plasma cobalamin on percentage of uAs metabolites.
%iAs %MMA %DMA
Parameter estimate 
(95% CI) p-Valuea p-Valueb
Parameter estimate 
(95% CI) p-Valuea p-Valueb
Parameter estimate 
(95% CI) p-Valuea p-Valueb
Total (n = 766)c –0.10 (–0.17 to –0.02) 0.01 0.12 (0.05 to 0.20) 0.001 –0.01 (–0.03 to 0.006) 0.16
Females (n = 471)d –0.12 (–0.22 to –0.01) 0.03 0.45 0.17 (0.07 to 0.26) 0.0009 0.14 –0.02 (–0.04 to 0.009) 0.19 0.69
Males (n = 295)d –0.06 (–0.17 to 0.05) 0.31 0.05 (–0.07 to 0.17) 0.38 –0.01 (–0.04 to 0.02) 0.51
Folate sufficient (n = 365)c –0.17 (–0.30 to –0.03) 0.02 0.06 0.20 (0.11 to 0.30) < 0.0001 0.04 –0.02 (–0.05 to 0.01) 0.22 0.54
Folate deficient (n = 401)c –0.02 (–0.09 to 0.05) 0.64 0.05 (–0.07 to 0.16) 0.41 –0.008 (–0.03 to 0.02) 0.54
Water As < 50 µg/L (n = 310)c –0.25 (–0.40 to –0.09) 0.002 0.005 0.16 (0.02–0.30) 0.03 0.47 0.003 (–0.02 to 0.03) 0.86 0.24
Water As > 50 µg/L (n = 456)c –0.0008 (–0.08 to 0.07) 0.98 0.10 (0.02–0.18) 0.02 –0.02 (–0.05 to 0.008) 0.16
ap-Value for the test of significance of the parameter estimate. bp-Value from the Wald test for differences in stratum-specific estimates (male vs. female, folate sufficient vs. deficient, 
and water As < 50 µg/L vs. > 50 µg/L). cAdjusted for log age (continuous), sex, log urinary creatinine (continuous), log total uAs (continuous), and log BMI (continuous). dAdjusted for all 
variables in (c) except sex.
Figure 2. Methylation of arsenite by methyl-
cobalamin by incubation time and molar ratio of 
CH3B12:AsIII at pH 7.4. AsIII and CH3B12 were com-
bined in Tris-HCl buffer in the presence of GSH, and 
aliquots were analyzed by HPLC-ICP-MS over time.
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(Zablotska et al. 2008). Serum concentrations 
of cobalamin were also not associated with 
the odds of As-induced premalignant skin 
lesions in a case-control study in West Bengal, 
India (Chung et al. 2006). The interpreta-
tion of these findings is limited by the use 
of prevalent cases of skin lesions (Zablotska 
et al. 2008) and by the measurement of blood 
concentrations of cobalamin from samples 
obtained after the development of skin lesions 
(Chung et al. 2006). However, the findings 
are consistent with our nested case-control 
study in Bangladesh in which baseline folate 
deficiency and hyperhomocysteinemia, but 
not cobalamin, were associated with a roughly 
70% increased risk for development of skin 
lesions at a 2-year follow-up visit (Pilsner 
et al. 2009). Our current findings, when com-
pared with our previous cross-sectional study 
(Gamble et al. 2005b), suggest that associa-
tions between cobalamin concentrations and 
As metabolism may only be apparent when 
a full range of cobalamin concentrations 
(including deficient individuals) is examined. 
Our results also show that the higher urinary 
%MMA among cobalamin-sufficient adults 
than among cobalamin-deficient adults, 
although statistically significant, is modest. 
This may help to explain the lack of an asso-
ciation between cobalamin and As-induced 
skin lesions in previous studies. 
In two other studies, researchers examined 
cobalamin in relation to As among pregnant 
Bangladeshi women. Li et al. (2008) reported 
that among 753 women, 60% of whom were 
cobalamin deficient, plasma cobalamin con-
centrations were not associated with uAs 
metabolites at gestational week 14. However, 
there was a suggestion that increasing plasma 
cobalamin concentrations were associated with 
decreased %iAs (mean %iAs for lowest and 
highest tertiles of plasma cobalamin were 13.7 
and 11.7, respectively) and increased %DMA 
(mean %DMA for lowest and highest ter-
tiles of plasma cobalamin were 76.5 and 79.2, 
respectively) among women with moderate 
uAs concentrations (58–209 µg/L). Li et al. 
(2008) suggested that the observed lack of a 
strong association between the nutrients exam-
ined and As metabolism may have been due 
to enhanced efficiency of As methylation dur-
ing pregnancy related to increased synthesis 
of choline (Zeisel 2006). It is also possible 
that this result is related to prenatal folic acid 
supplement use. Hall et al. (2007), in a study 
of 101 maternal–newborn pairs, reported that 
maternal cobalamin concentration was sig-
nificantly inversely associated with cord blood 
iAsV. In this study, maternal cobalamin was 
also inversely correlated with maternal uri-
nary %iAs (r = –0.20, p = 0.05) and positively 
correlated with %DMA (r = 0.18, p = 0.09), 
although these associations were of borderline 
statistical significance (Hall et al. 2007). 
Our findings of stronger associations 
between plasma cobalamin and uAs metabo-
lites among women than among men are 
likely explained by the higher prevalence of 
cobalamin deficiency among these women. 
The modification of the associations between 
cobalamin and uAs metabolites by folate status 
is consistent with the role of 5-methyl THF 
as the methyl donor for the conversion of 
homocysteine to methionine by methio  nine 
synthase, the reaction for which cobalamin 
is a required cofactor and 5-methyl THF is 
a cosubstrate; methionine synthase activity is 
reduced when 5-methyl THF is limiting. It 
is unclear, however, why in the presence of 
adequate folate, cobalamin is not associated 
with increased %DMA. We hypothesize that 
cobalamin facilitates the first methylation step 
and that the reaction has a tendency to stop 
at MMA, although the underlying mecha-
nism cannot be determined from our data. 
Interestingly, Drobna et al. (2006) found that 
shRNA silencing of AS3MT in HepG2 cells 
reduced the percentage of 73iAsIII methylated 
to DMA from 53% to 11%, whereas the 
synthesis of MMA actually increased from 
10% to 13% of total 73As. Similarly, AS3MT 
knockout mice synethsize as much, if not 
more, MMA than wild-type mice (Drobna et 
al. 2009). These results strongly suggest the 
presence of an AS3MT-independent mecha-
nism for MMA biosynthesis and prompted us 
to conduct an in vitro experiment.
Our in vitro methylcobalamin experiments, 
modeled after those of Zakharyan and Aposhian 
(1999), produced similar findings and support 
their suggestion that small amounts of MMA 
may be formed non  enzymatically. Our experi-
ments differed from those of Zakharyan and 
Aposhian in that we examined the effect of 
pH and the molar ratio of CH3B12:arsenite 
on the production of MMA, and we omit-
ted SAM, a possible source of methyl groups, 
from the reaction mixture. Not surprisingly, 
our results indicated that increasing the molar 
ratio of CH3B12:arsenite resulted in increased 
production of MMA. We also observed that 
the nonenzymatic methylation of arsenite by 
methylcobalamin was increased at pH levels 
closer to the normal pH of blood and other 
tissues than at pH 7.8. Whether the findings 
from our in vitro experiment, along with those 
of Zakharyan and Aposhian (1999), are rele-
vant in vivo deserves further investigation. 
The implications of our finding that coba-
lamin is associated with %MMA, but not with 
%DMA, are not entirely clear. However, a 
higher %MMA and lower %DMA in urine 
has been associated with increased risks of 
As-related skin lesions, skin cancer, bladder 
cancer, and peripheral vascular disease (Ahsan 
et al. 2007; Chen et al. 2003a, 2003b; Huang 
et al. 2008; Tseng 2007). These studies have 
measured %MMAV+III in urine because of 
the difficulty of preserving the valence state. 
However, MMAV is relatively nontoxic, 
whereas MMAIII is highly toxic (Styblo et al. 
2002; Wang et al. 2007). Tseng (2007) sug-
gested that the associations between MMA in 
urine and disease risks may actually be due to 
MMAIII, which is not stable and is readily oxi-
dized to MMAV. Our observed positive asso-
ciation between cobalamin and total %MMA 
in urine, taken together with recent evidence 
regarding the toxicity of MMAIII, suggests that 
any influence of cobalamin on As-associated 
disease risk may not be favorable. 
We measured plasma total cobalamin 
rather than methylmalonic acid or holo-
trans  cobalamin, two measurements that may 
be more sensitive indicators of cobalamin 
deficiency (Clarke et al. 2007; Obeid and 
Herrmann 2007). Although we may under-
estimate the prevalence of cobalamin deficiency, 
the statistical associations between cobalamin 
and uAs metabolites are dependent upon the 
ranking of individuals, not upon absolute con-
centrations of cobalamin. The interpretation of 
our findings is also limited by the expression 
of uAs metabolites as percentages, given that 
these values are relative to each other. However, 
meaningful patterns of association can still be 
detected when the data are expressed in this 
manner. We also did not have a measure of 
plasma choline or betaine, which may both be 
relevant sources of methyl groups for As methy-
lation. In addition, we were not able to adjust 
for possible confounding by dietary intake of 
other nutrients that may influence As metab-
olism and also be correlated with cobalamin 
intake (such as methio  nine or creatine). 
In summary, among this group of 
Bangladeshi adults with a high prevalence of 
cobalamin deficiency, cobalamin appeared 
to facilitate the methylation of iAs to MMA, 
particularly among women and among folate-
sufficient individuals. The results of our in vitro 
experiment confirm that incubation of iAs with 
methylcobalamin can generate small amounts 
of MMA nonenzymatically. This finding is 
consistent with in vivo cell culture studies sug-
gesting that alternative mechanisms for biosyn-
thesis of MMA, independent of AS3MT, likely 
exist (Drobna et al. 2006, 2009). Given the 
recent evidence suggesting that MMAIII may 
be the most toxic As metabolite, our findings 
raise the possibility that, in contrast to folate, 
cobalamin supplementation may not favorably 
influence As metabolism.
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